ResidenceTimer™ Off-the-Shelf Assays

Kinase Panel

The table contains an overview of kinase assays that are available for measurement of target residence time measurement.

Kinase Domain Reference therapeutics Preview details
ABL (ABL1) full length bosutinib, dasatinib, imatinib, ponatinib [pdf]
AKT1 catalytic domain GSK690693 [pdf]
AKT2 catalytic domain GSK690693 [pdf]
ALK cytoplasmic domain alectinib, crizotinib [pdf]
ALK [L1196M] cytoplasmic domain brigatinib, crizotinib [pdf]
ALK [G1202R] cytoplasmic domain lorlatinib [pdf]
AurA (AURKA) full length MK-5108, pan-Aurora inhibitors [pdf]
AurB (AURKB)* full length MK-5108, pan-Aurora inhibitors [pdf]
AXL cytoplasmic domain crizotinib, sunitinib [pdf]
BMX full length bosutinib, dasatinib [pdf]
BRAF catalytic domain dabrafenib, vemurafenib [pdf]
BRK full length ibrutinib [pdf]
BTK full length dasatinib, ibrutinib, ponatinib [pdf]
BTK* full length dasatinib, ibrutinib, ponatinib [pdf]
BTK [T316A] full length acalabrutinib, fenebrutinib [pdf]
BTK [T316A]* full length fenebrutinib, ibrutinib [pdf]
BTK [T474I] full length ibrutinib [pdf]
BTK [T474I]* full length ARQ-531, ibrutinib [pdf]
BTK [T474S]* full length ARQ-531, ibrutinib [pdf]
BTK [C481S] full length fenebrutinib, ibrutinib [pdf]
BTK [C481S]* full length fenebrutinib [pdf]
CDC2 (CDK1)/CycA2 full length staurosporine, dinaciclib [pdf]
CDK2/CycA2 full length dinaciclib, PHA-793887 [pdf]
CDK2/CycE1 full length SNS-032 [pdf]
CDK4/CycD1 full length dinaciclib [pdf]
CDK4/CycD3 full length abemaciclib, dinaciclib, palbociclib, ribociclib [pdf]
CDK5/p25 full length dinaciclib, SNS-032 [pdf]
CDK6/CycD1 full length dinaciclib [pdf]
CDK7/CycH/MAT1 full length dinaciclib, pan-CDK inhibitors [pdf]
CDK8/CycC full length staurosporine [pdf]
CDK9/CycK full length dinaciclib, PHA-793887 [pdf]
CDK9/CycT1 full length dinaciclib, pan-CDK inhibitors [pdf]
CDK9/CycT2 full length staurosporine, dinaciclib [pdf]
CHK1 (CHEK1) full length bosutinib, sunitinib [pdf]
CSF-1R/FMS cytoplasmic domain dasatinib [pdf]
DDR2* cytoplasmic domain dasatinib, imatinib, ponatinib, sorafenib [pdf]
EGFR cytoplasmic domain afatinib, erlotinib, gefitinib [pdf]
EGFR [d746-750] cytoplasmic domain gefitinib, erlotinib, afatinib [pdf]
EGFR [d746-750/C797S] cytoplasmic domain gefitinib, erlotinib, afatinib [pdf]
EGFR [T790M] cytoplasmic domain afatinib [pdf]
EGFR [T790M/L858R] cytoplasmic domain osimertinib [pdf]
EGFR [C797S/L858R] cytoplasmic domain gefitinib, erlotinib, afatinib [pdf]
EGFR [L858R] cytoplasmic domain afatinib [pdf]
EPHA2 cytoplasmic domain BMS-777607, dasatinib, staurosporine [pdf]
FAK (PTK2) truncated human crizotinib [pdf]
FGFR1 cytoplasmic domain infigratinib, ponatinib [pdf]
FGFR1* cytoplasmic domain infigratinib, ponatinib [pdf]
FGFR2 cytoplasmic domain infigratinib [pdf]
FGFR3* cytoplasmic domain infigratinib, sunitinib [pdf]
FGFR4 cytoplasmic domain infigratinib, sunitinib [pdf]
FLT3 cytoplasmic domain dasatinib, imatinib [pdf]
FYN [isoform a] full length dasatinib, ponatinib, regorafenib [pdf]
GCN2 (EIF2AK4) full length A-92 [pdf]
GSK3β (GSK3B) full length abemaciclib, staurosporine [pdf]
HPK1 (MAP4K1) catalytic domain bosutinib [pdf]
IGF1R* catalytic domain cabozantinib, GSK-1838705, staurosporine [pdf]
IKKα (CHUK)  full length IKKβ inhibitor [pdf]
IKKα (CHUK) [K44A] inactive full length IKKβ inhibitor [pdf]
IRAK4 full length crizotinib, sunitinib [pdf]
Kinase Domain Reference therapeutics Preview details
ITK* full length crizotinib, sunitinib [pdf]
JAK2 catalytic domain staurosporine [pdf]
KDR (VEGFR2) cytoplasmic domain vandetanib [pdf]
KIT* cytoplasmic domain masitinib, pazopanib, staurosporine [pdf]
LCK full length ponatinib, regorafenib [pdf]
LYNa full length ponatinib, regorafenib, tamatinib [pdf]
MAP2K1 inactive full length crizotinib, dasatinib, trametinib [pdf]
MAP3K5 catalytic domain bosutinib, staurosporine, sunitinib [pdf]
MER cytoplasmic domain BMS-777607 [pdf]
MET cytoplasmic domain crizotinib [pdf]
p38α (MAPK14) truncated human sorafenib, p38 MAPK inhibitors [pdf]
p38α (MAPK14) inactive truncated human sorafenib, p38 MAPK inhibitors [pdf]
PAK4 full length bosutinib, GSK690693, staurosporine [pdf]
PDGFRα (PDGRFA) cytoplasmic domain nintedanib, axitinib, crenolanib, gilteritinib [pdf]
PDGFRα (PDGRFA)* cytoplasmic domain nintedanib, axitinib, crenolanib, gilteritinib [pdf]
PDGFRβ (PDGRFB) cytoplasmic domain nintedanib, axitinib, crenolanib, gilteritinib [pdf]
PDGFRβ (PDGRFB)* cytoplasmic domain nintedanib, axitinib, crenolanib, gilteritinib [pdf]
PIK3CA/PIK3R1 full length dactolisib, pictilisib [pdf]
PIK3CA [R88Q]/PIK3R1* full length idelalisib [pdf]
PIK3CA [P539R]/PIK3R1* full length idelalisib [pdf]
PIK3CA [E542K]/PIK3R1* full length idelalisib [pdf]
PIK3CA [E545K]/PIK3R1* full length idelalisib [pdf]
PIK3CA [H1047R]/PIK3R1* full length idelalisib [pdf]
PIK3CB/PIK3R1 full length apitolisib [pdf]
PIK3CD/PIK3R1 full length duvelisib, idelalisib [pdf]
PIK3CG full length apitolisib, dactolisib, duvelisib [pdf]
PIK3CG/PIK3R5 full length apitolisib, duvelisib [pdf]
PKACa (PRKACA) full length A-674563 [pdf]
PKN1 full length GSK690693 [pdf]
PLK1 full length GSK461364 [pdf]
PYK2 (PTK2B)* full length crizotinib [pdf]
RAF1 (CRAF) catalytic domain dabrafenib [pdf]
RET cytoplasmic domain dasatinib, ponatinib, regorafenib, sorafenib, vandetanib [pdf]
RET [G691S]* cytoplasmic domain staurosporine [pdf]
RET [Y791F]* cytoplasmic domain staurosporine [pdf]
RET [V804M] cytoplasmic domain staurosporine [pdf]
RET [V804M]* cytoplasmic domain staurosporine [pdf]
RET [S891A]* cytoplasmic domain staurosporine [pdf]
RET [M918T]* cytoplasmic domain staurosporine [pdf]
ROCK1 catalytic domain GSK 429286A [pdf]
SRC full length A770041, ponatinib, regorafenib [pdf]
SRPK1 full length staurosporine [pdf]
SYK full length staurosporine [pdf]
SYK* full length staurosporine [pdf]
TGFβR1 (TGFBR1) catalytic domain SB 431542 [pdf]
TIE2* cytoplasmic domain ponatinib, vandetanib [pdf]
TNIK catalytic domain bosutinib, sunitinib [pdf]
TRKA (NTRK1) cytoplasmic domain AZ23, ponatinib [pdf]
TRKA (NTRK1)* cytoplasmic domain AZ23, ponatinib [pdf]
TRKB (NTRK2) cytoplasmic domain ponatinib [pdf]
TRKB (NTRK2)* cytoplasmic domain AZ23, ponatinib [pdf]
TRKC (NTRK3)* catalytic domain AZ23, sorafenib [pdf]
TYRO3 cytoplasmic domain BMS-777607 [pdf]
TYRO3* cytoplasmic domain BMS-777607 [pdf]
WEE1 catalytic domain AZD1775 [pdf]
YES (YES1) full length saracatinib, staurosporine [pdf]
* Pre-activated by treatment with ATP after purification and before immobilization
BACK TO HOME